A Phase 2 interventional study of Antithrombin III in Antithrombin III Deficiency and Covid19, sponsored by Enrique Ginzburg. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-07.
Sponsored by Enrique Ginzburg · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,860 studies in COVID-19 with a site in United States, this one is the 802nd largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 350 in phase 2, and was the 1,145th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,860 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 482 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 92 across the 1,322 interventional studies, 300 across the 521 observational. Of the 1,415 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,860 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Enrique Ginzburg as lead sponsor.
Enrique Ginzburg has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
84 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,860 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.
Drug: Antithrombin III
Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.
Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.
Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).
Also known as: Thrombate III
Change in ISTH DIC Score
As measured by the International Society of Thrombosis and Haemostasis Disseminated Intravascular Coagulation scale (ISTH DIC) which has a total score ranging from 0-8 with a score of 5 and higher indicating overt DIC.
Time frame: Baseline, Day 9
Change in D-Dimer Levels
D-Dimer levels assessed from blood samples will be evaluated in mcg/ml D-Dimer Units (DDU)
Time frame: Baseline, Day 9
Change in Fibrinogen Levels
Fibrinogen levels assessed from blood samples will be evaluated in mg/dL.
Time frame: Baseline, Day 9
Change in Prothrombin Time
Prothrombin time assessed from blood samples will be evaluated in seconds.
Time frame: Baseline, Day 9
Length of Hospital Stay
Length of Hospital Stay reported in days.
Time frame: Up to 60 days
Mortality Rate
The number of participants with reported death.
Time frame: Up to 60 days
Pulmonary Function
Pulmonary Function will be reported as the mean days the participant was on any of the following: mechanical ventilation and/or Extracorporeal Membrane Oxygenation (ECMO) use.
Time frame: Up to 60 days
Change in SOFA Scores
Sequential Organ Failure Assessment (SOFA) is scored from 0-4 with the higher score indicating more organ failure.
Time frame: Baseline, Day9
Change in SOFA Respiratory Sub Score
SOFA Respiratory Sub Score is scored from 0-4 with the higher score indicating worse organ failure.
Time frame: Baseline, Day 9
Number of Events of Venous Thromboembolism
Number of events of venous thromboembolisms from admission to hospital discharge.
Time frame: Up to 60 days
Number of Events of Major Bleeding
Number of events of major bleeding from admission to hospital discharge.
Time frame: Up to 60 days
| Milestone | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Started | 20 | 20 | 12 |
| Completed | 15 | 20 | 12 |
| Not completed | 5 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Participant discharged before receiving intervention | 3 | 0 | 0 |
| Milestone | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Started | 15 | 20 | 12 |
| Completed | 15 | 20 | 12 |
| Not completed | 0 | 0 | 0 |
As measured by the International Society of Thrombosis and Haemostasis Disseminated Intravascular Coagulation scale (ISTH DIC) which has a total score ranging from 0-8 with a score of 5 and higher indicating overt DIC.
| score on a scale | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Change in ISTH DIC Score | 0.27 ± 1.71 | 0 ± 1.73 | 0 ± 1.65 |
D-Dimer levels assessed from blood samples will be evaluated in mcg/ml D-Dimer Units (DDU)
| mcg/ml DDU | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Change in D-Dimer Levels | -1.97 ± 5.60 | 0.4 ± 3.18 | 0.25 ± 2.18 |
Fibrinogen levels assessed from blood samples will be evaluated in mg/dL.
| mg/dL | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Change in Fibrinogen Levels | -102.1 ± 233.7 | -123 ± 215.1 | -111 ± 307.5 |
Prothrombin time assessed from blood samples will be evaluated in seconds.
| Seconds | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Change in Prothrombin Time | 0.01 ± 2.07 | 0.31 ± 1.27 | 0.59 ± 1.39 |
Length of Hospital Stay reported in days.
| Days | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Length of Hospital Stay | 13 ± 15.1 | 6 ± 8.35 | 8.5 ± 9.46 |
The number of participants with reported death.
| Participants | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Mortality Rate | 2 | 3 | 3 |
Pulmonary Function will be reported as the mean days the participant was on any of the following: mechanical ventilation and/or Extracorporeal Membrane Oxygenation (ECMO) use.
| Days | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Pulmonary Function | 1.33 ± 5.16 | 2.2 ± 6.70 | 3.08 ± 6.97 |
Sequential Organ Failure Assessment (SOFA) is scored from 0-4 with the higher score indicating more organ failure.
| score on a scale | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Change in SOFA Scores | 0.43 ± 3.41 | 1.23 ± 3.33 | 0.64 ± 2.27 |
SOFA Respiratory Sub Score is scored from 0-4 with the higher score indicating worse organ failure.
| score on a scale | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Change in SOFA Respiratory Sub Score | -0.67 ± 0.98 | -0.07 ± 0.70 | -0.17 ± 1.69 |
Number of events of venous thromboembolisms from admission to hospital discharge.
| Events | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Number of Events of Venous Thromboembolism | 0 | 0 | 3 |
Number of events of major bleeding from admission to hospital discharge.
| events | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only |
|---|---|---|---|
| Number of Events of Major Bleeding | 0 | 0 | 2 |
Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AT3 Less Than 100% With SOC Plus AT3 Supplement | 2/15 (13.3%) | 0/15 (0%) | 5/15 (33.3%) |
| AT3 Less Than 100% With SOC Only | 3/20 (15%) | 0/20 (0%) | 5/20 (25%) |
| AT3 of 100% or More, With SOC Only | 3/12 (25%) | 0/12 (0%) | 8/12 (66.7%) |
| Event | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 of 100% or More, With SOC Only |
|---|---|---|---|
| Acute Kidney InjuryRenal and urinary disorders | 2/15 | 1/20 | 4/12 |
| Worsening Respiratory FailureRespiratory, thoracic and mediastinal disorders | 1/15 | 3/20 | 4/12 |
| ShockGeneral disorders | 1/15 | 2/20 | 2/12 |
| Atrial FibrillationCardiac disorders | 0/15 | 0/20 | 2/12 |
| AnemiaBlood and lymphatic system disorders | 1/15 | 1/20 | 2/12 |
| Pulseless Electrical ActivityCardiac disorders | 1/15 | 3/20 | 1/12 |
| Heart Failure with reduced Ejection FractionCardiac disorders | 0/15 | 0/20 | 1/12 |
| Deep Vein ThrombosisBlood and lymphatic system disorders | 0/15 | 0/20 | 1/12 |
| Ureterovesical Junction (UVJ) CalculusRenal and urinary disorders | 0/15 | 0/20 | 1/12 |
| Cardiac ArrestCardiac disorders | 0/15 | 0/20 | 1/12 |
| Age, Categorical(Participants) | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 14 | 9 | 38 |
| >=65 years | 5 | 6 | 3 | 14 |
| Sex: Female, Male(Participants) | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only | Total |
|---|---|---|---|---|
| Female | 6 | 7 | 4 | 17 |
| Male | 14 | 13 | 8 | 35 |
| Ethnicity (NIH/OMB)(Participants) | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 14 | 7 | 31 |
| Not Hispanic or Latino | 10 | 6 | 5 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AT3 Less Than 100% With SOC Plus AT3 Supplement | AT3 Less Than 100% With SOC Only | AT3 More Than 100% With SOC Only | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 5 | 4 | 17 |
| White | 12 | 14 | 8 | 34 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Mar 2022, 8 months.
Results were first posted in Sep 2022, 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Antithrombin III